Medicare commences protection evaluation for Biogen Alzheimer’s drug

Hello, everybody, and how are you right now? Cloudy skies are hovering this morning above the Pharmalot campus, wherever points have settled down now that the shorter individual has remaining for gainful employment and the formal mascot has assumed his official snoozing posture. As for us, we are dutifully concocting a handful of essential cups of stimulation as we dig in for one more hectic working day. No question, you can relate. So time to get cracking. As generally, we have assembled some items of curiosity. So hoist your very own cup to a profitable day, and fall us a line when a little something attention-grabbing occurs. …

The Centers for Medicare & Medicaid Solutions announced ideas to start a approach that could limit entry to the controversial new Alzheimer’s drug from Biogen (BIIB) — the initially signals from the agency about what will be an enormously consequential determination for Biogen, the Medicare method by itself, and people with the disorder, STAT writes. The method, identified as a Countrywide Coverage Perseverance evaluation, makes certain that protection for the drug is uniform throughout the state as an alternative of leaving decisions to regional contractors.

Unlock this write-up by subscribing to STAT+ and delight in your to start with 30 times cost-free!

GET Started off